BS EN ISO 15197:2015 体外诊断检验系统-糖尿病管理中自测用血糖监测系统的要求(英文版)
- 格式:pdf
- 大小:1.83 MB
- 文档页数:60
关于血糖监测产品的质量控制说明1. 为什么要做质控? 在血糖监测产品使用过程中,这是唯一的方法来确保血糖仪和所使用的试纸能够作为一个整体而正常工作,而只有当质控结果在目标范围内时(通常印在试纸瓶标签上),才能使用该血糖仪及所使用的血糖试纸用于患者的血糖监测.2. 何时进行质控? 通常按照血糖监测产品厂家的建议, 在以下情况下进行质控测试: 1) 每当使用一瓶新试纸时; 2)当怀疑血糖仪或血糖试纸有问题时; 3)当血糖仪曾跌落或损坏时; 4)当测试结果与患者临床症状不一致时5)当清洁血糖仪后等需要进行质控测试. 考虑到医院临床使用的实际情况, 还需要根据临床医疗机构的要求进行适时的质控检测.3. 使用何种质控物质? 通常质控物质分为:a) 基本控制物(Primary Controls),它是指参考物质已经通过明确的方法被确定了一个固定值,如:1摩尔葡萄糖(C6H12O6)就是 180克(179.8561克);1摩尔乙醇的质量就是46克等; 这类物质通常在标准实验室才能拥有和定义,一般医院检验科不具备此类物质和发布此类物质的条件和要求b) 第二类质控物(secondary Controls), 它是指物质已经通过一个可接受的参考方法获得了一个固定值, 如: 25摄氏度条件下的5%葡萄糖溶液(约0.2778摩尔/升); 0.9%生理氯化钠溶液(约0.21摩尔/升)等.这类质控物有一个明显特点: 它有一个明确确定的值而不是一个范围,因此,常用于医院检验科的校准液或质控品.c) 第三类质控物(Tertiary Controls), 它是指物质通过常规方式的重复测量获得的一个值或范围, 如: 血糖质控液. 目前所有的血糖仪厂家提供的质控液都是属于第三类质控物. 这种第三类质控液可以评估所使用的血糖仪和血糖试纸的精确性(重复性)和葡萄糖的回收率(也称为相对准确性: 回收率是反应待测物在样品分析过程中的损失的程度,损失越少,回收率越高. 如果取质控品的浓度为1PPM,就是1毫克/升,而测试所得的标准数据为0.99毫克/升,就是说所测试的系统的回收率是99%,说明方法的准确性非常高。
即时检测(POCT)信息化质量管理中国专家共识摘要即时检测(POCT)信息化质量管理应遵循统一的术语和定义,POCT信息化管理、管理规范和应用规范应遵守一定的标准。
本专家共识的发布对于规范POCT信息化质量管理起到积极的推动作用。
即时检测(point-of-care-testing,POCT)由于具有快速、小型、便携等优点,临床应用日益广泛,其质量管理越来越受到医疗机构重视。
信息化手段作为进行POCT质量管理的有效方式,其相关功能及应用要求是目前医疗机构亟需行业指南,对于提升医疗机构医疗质量管理水平,完善POCT管理体系与加速医疗机构信息化建设具有重要的意义。
一、适用范围与目的随着POCT信息化建设不断发展,其管理需不断规范完善。
现组织国内相关学科的专家对POCT信息化管理系统(下称"管理系统")的选择与建立、体系管理功能以及数据管理功能进行讨论形成共识,供临床应用参考。
本共识旨在通过信息化手段提升POCT院内质量管理水平,仅适用于我国各级医疗机构,不适用于患者自测型即时检测。
二、术语定义与解释下列术语与定义适用于本文件。
1.即时检测(point-of-care-testing,POCT)[1]:为近患检测/床旁检测near-patient testing(NPT)。
2.质量(quality)[2]:客体的一组固有特性满足要求的程度。
3.质量管理体系(quality management system)[3]:在质量方面指挥和控制组织的管理体系。
4.卫生信息交换标准(Health Level 7,HL7)[4]:标准化的卫生信息传输协议,是医疗领域不同应用之间电子传输协议。
HL7汇集了不同厂商用来设计应用软件之间接口的标准格式。
它将允许各个医疗机构在异构系统之间,进行数据交互。
5.无线局域网媒体访问控制和物理层规范[5][Wireless LAN Medium Access Control,(MAC)and Physical Layer(PHY) Specifications]:通过无线电技术,实现系统间的远程通信和信息交换,此处指检测设备与信息化管理系统之间的数据交换,其使用的技术符合国家发布的相关技术标准和规范。
血糖仪使用说明书版本号:QI-QW-VPE医疗器械注册证编号/产品技术要求编号:湘械注准20162400328医疗器械生产许可证编号:湘食药监械生产许20150053号说明书的修订日期:2017年6月售后服务单位:三诺生物传感股份有限公司住所/生产地址:长沙高新技术产业开发区谷苑路265号E-mail:*****************http:// 邮编:410205全国客服专线:400 887 0036注册人/生产企业产品型号:安稳+Code 、安稳+、安稳+Voice 、安稳+AirBlood GlucoseMeter目 录一、适用范围、规格型号、配套试条、检测方法和原理 (1)1.1 适用范围 (1)1.2 规格型号 (1)1.3 配套试条 (1)1.4 检测方法和原理 (1)二、仪器主要结构及其各配件组成结构和示意图 (2)2.1主要结构组成 (2)2.2血糖仪及各配件组成示意图 (2)三、显示说明 (5)四、使用操作 (7)4.1安装电池 (7)4.2设置校正码(仅适用于安稳+Code) (8)4.3测试 (8)4.4 结果查询 (13)4.5省电模式 (14)14.1 指南和制造商的声明–电磁发射 ………………………………37 14.2 指南和制造商的声明–电磁抗扰度 ……………………………38 14.3 指南和制造商的声明–电磁抗扰度………………………………39 14.4 便携式及移动式射频通信设备和设备或系统之间的推荐隔离距................................................................................. 41 附录1 保修卡(客户自留) ......................................................44附录2 保修卡(返生产厂家) (45)十四、电磁兼容性声明 ……………………………………………………36目 录离目 录4.7 指示灯功能(适用于安稳+Voice血糖仪) ..............................15五、检查系统 ........................................................................17 5.1 何时需要检查系统.........................................................17 5.2 质控检查步骤...............................................................18 5.3 质控液测试结果超出范围的可能原因及措施........................18 六、保存和保养.....................................................................20七、保修 ...........................................................................21八、使用注意事项 ..................................................................22九、故障 ..............................................................................23十、血糖测试系统测量性能 ......................................................31十一、产品性能参数 ...............................................................33十二、配件清单 .....................................................................34十三、符号的解释 (35)4.6 语音功能(适用于安稳+Voice血糖仪) (14)2.2.3安稳+示意图2.2.2安稳+Voice示意图2.2.4安稳+Air示意图2.2.5采血笔示意图注意:血糖仪只能与“配套试条”中注明的血糖试条配合使用,请勿与其他公司产品或本公司其他型号产品混用。
附件持续葡萄糖监测系统注册技术审查指导原则本指导原则是对持续葡萄糖监测系统的一般要求,注册申请人应依据具体产品的特性对注册申报资料的内容进行充实和细化。
注册申请人还应依据具体产品的特性确定其中的具体内容是否适用,若不适用,需具体阐述其理由及相应的科学依据。
本指导原则是对注册申请人和审查人员的指导性文件,但不包括注册审批所涉及的行政事项,亦不作为法规强制执行,如果有能够满足相关法规要求的其他方法,也可以采用,但是需要提供详细的研究资料和验证资料。
应在遵循相关法规的前提下使用本指导原则。
本指导原则是在现行法规和标准体系以及当前认知水平下制定的,随着法规和标准的不断完善,以及科学技术的不断发展,本指导原则相关内容也将适时进行调整。
一、适用范围本指导原则适用于以电化学为基本原理,通过微创传感器手段,检测组织液中葡萄糖浓度的回顾式或实时持续葡萄糖监测系统。
持续葡萄糖监测系统接收器中内置血糖检测模块的产品还应满足血糖仪注册技术审查指导原则的相关内容。
接收器带有胰岛素泵功能的产品应考虑增加胰岛素泵的适用要求。
二、产品综述资料(一)概述持续葡萄糖监测(Continuous Glucose Monitoring,CGM)系统,通常称为动态葡萄糖监测系统,属于医疗器械分类目录(2018版)中07医用诊察和监护器械,一级产品类别为04监护设备,二级产品类别为03动态血糖/葡萄糖监测设备。
在医疗器械分类目录(2002版)中属于6821医用电子仪器设备,03有创医用传感器。
产品从数据提供方式上可分为实时/回顾两种类型,从校准情况上可分为校准/无校准两种类型。
1.实时/回顾:根据产品在使用过程中,是否能在第一时间显示出葡萄糖数据,而非在佩戴结束后将数据上传后才能获得,分为实时持续葡萄糖监测系统和回顾式持续葡萄糖监测系统。
2.校准/无校准:根据产品在使用过程中,是否需要使用者输入指尖测量血糖或其他血糖值进行校准,分为需校准持续葡萄糖监测系统和无校准持续葡萄糖监测系统。
血糖监测系统通用技术要求2021摘要:一、血糖监测系统的背景和重要性二、血糖监测系统的技术要求三、血糖监测系统的性能评估四、血糖监测系统的应用前景正文:血糖监测系统是一种用于监测血糖水平的设备,对于糖尿病患者以及健康人群来说,它具有重要的意义。
在2021年,血糖监测系统的通用技术要求已经得到了明确的规范。
本文将详细介绍这些技术要求,以及血糖监测系统的性能评估和应用前景。
首先,血糖监测系统的技术要求主要包括以下几个方面:准确度、精密度、稳定性、响应时间、检测限、干扰物质、报警系统等。
其中,准确度和精密度是衡量血糖监测系统性能的重要指标,稳定性则关系到血糖监测系统的使用寿命。
响应时间、检测限和干扰物质则影响到血糖监测系统的实时性和可靠性。
而报警系统则是血糖监测系统的一个重要功能,它可以在血糖水平超出正常范围时及时发出警报,提醒患者采取相应的措施。
其次,血糖监测系统的性能评估也是一个重要的环节。
性能评估主要包括准确度评估、精密度评估、稳定性评估、响应时间评估、检测限评估、干扰物质评估和报警系统评估。
通过这些评估,可以确保血糖监测系统的性能达到预期的要求,为患者提供准确的血糖信息。
最后,血糖监测系统的应用前景非常广阔。
随着科技的不断发展,血糖监测系统的性能将不断提高,体积也将越来越小,这将使血糖监测系统更加便携,更容易被患者接受。
同时,血糖监测系统的价格也将越来越亲民,使更多的人能够承受得起。
因此,血糖监测系统在未来将得到更广泛的应用,不仅可以帮助糖尿病患者更好地控制血糖,还可以用于健康人群的血糖监测,预防糖尿病的发生。
总之,血糖监测系统是一种非常重要的医疗设备,它的通用技术要求已经得到了明确的规范。
血糖分析仪技术要求20150114医疗器械产品技术要求医疗器械产品技术要求编号:血糖分析仪1.产品型号/规格及其划分说明1.1血糖分析仪1.1.1规格标记方法1.1.2规格血糖分析仪型号:eB-D44。
2•性能指标2.1外观血糖分析仪盒外观整洁,标识清晰,表面应标明批号、效期2.2测量范围2.2.1测量重复性血糖分析仪重复测量结果的精密度应符合表1的要求。
表1:血糖仪测量重复性222在1.1mmol/L〜35.0mmol/L (20mg/dL〜630mg/dL)血糖值范围内,血糖分析仪测量结果偏差的95沁符合表2的要求;表2准确度要求2.3连接功能2.3.1蓝牙功能:血糖分析仪应能与指定设备进行蓝牙连接,将该血糖分析仪数据传输到指定设备。
2.3.2串口功能:血糖分析仪应能通过USB数据线与指定设备进行连接,将血糖分析仪数据传输到指定设备。
2.3.3 GPRS功能:血糖分析仪应能与指定设备或服务器进行GPRS功能连接,将该血糖分析仪数据传输到指定设备或服务器。
2.4正常开机功能血糖仪能正常开机2.5电气安全评价血糖分析仪应符合GB9706.1-2007的要求。
2.6环境试验要求血糖分析仪应符合GB/T 14710-2009中气候环境试验H 组、机械环境试验H 组及表2的要 求,运输试验应符合 GB/T14710-2009中第4章 的要求,电源电压适应能力试验应符合本标准 4.1d )中直流内部电源供电的要求。
表3环境实试验项目、试验要求及检测项目TIT:正常工作位置复间24最后全性2.42.12.42.44844-41 4 -41 2.7 V.V2.7电磁兼容性设备应满足YY0505-2005中规定的要求。
2.8血糖仪配件与我公司血糖仪产品配套使用的血糖仪配件(包含采血笔、采血针、血糖试纸试纸)为外购具有医疗器械注册证或注册登记的厂家生产的配件;3.检验方法试验材料A )血糖仪2台B )血糖试条C) 参考分析仪(YSI2300D)D )具有溯源性的血糖参考物质E)静脉血样或毛细血管血样F)添加适当抗凝剂的采血管G)低速离心机H)吸管I)参考分析仪用的比色杯或小试管J)企业提供的有关校准和质控程序的使用说明K)适当容量范围的一次性移液器3.1外观与结构目视观察和手感试验,结果应符合2.1规定。
2015年体外诊断量值溯源分析报告2015年7月目录一、量值溯源是检验医学标准化的唯一途径........................................................ 4.1、量值溯源有何意义........................................................................................................ 4...2、量值溯源是什么............................................................................................................ 4...3、如何简单解释量值溯源................................................................................................ 5..4、如何保证量值溯源........................................................................................................ 6...5、量值溯源难在何处........................................................................................................ 7...(1)量值溯源需要多年积累 (7)(2)量值溯源限定使用范围,不能直接产生经济效益,一般企业没有动力 (7)二、深化医改浪潮下量值溯源将成IVD 企业的核心竞争力 (8)1、促进医院检验科结果互认是必然趋势....................................................................... 8..2、什么是ISO15189 认证................................................................................................ 8..3、通过ISO15189 认证的实验室结果可全球互认 ...................................................... 9.4、大力推行ISO15189 认证将成必然趋势................................................................... 9.5、量值溯源是通过ISO15189 认证的必要条件,将成为IVD 企业竞争的重要指标................................................................................................................................................. 9 ....三、评价量值溯源能力的国际认证体系............................................................. 1.01、JCTLM :全球量值溯源能力最高评审机构 ........................................................... 1. 02、C NAS :国内实验室能力认证的最高机构................................................................ 1 23、I FCC-RELA :量值溯源能力直接比拼的大舞台.................................................... 1. 3四、行业重点企业简况 ..................................................................................................................................... 1..5.1、迈克生物:最具国际水准的中国体外诊断企业....................................................... 1. 62、美康生物:生化诊断龙头,全产业链延伸 ................................................................. 1.7量值溯源是检验医学标准化的唯一途径。
便携式血糖仪临床操作和质量管理指南1范围本文件规定了便携式血糖仪进入医疗机构应用的性能要求和使用其进行血糖监测的质量管理要求。
本文件适用于医疗机构使用便携式血糖仪开展血糖监测,不包括患者自我监测。
2规范性引用文件下列文件对于本文件的应用是必不可少的。
凡是注日期的引用文件,仅所注日期的版本适用于本文件。
凡是不注日期的引用文件,其最新版本(包括所有的修改单)适用于本文件。
GB/T19634—2005体外诊断检验系统自测用血糖监测系统通用技术条件3术语与定义下列术语和定义也适用于本文件。
3.1便携式血糖仪portable blood glucose meters可随身携带、操作便捷、在患者近旁使用、快速测定患者末梢血中葡萄糖浓度的设备。
其给出的葡萄糖测定浓度可以是末梢全血葡萄糖浓度,也可以校准为血浆葡萄糖浓度(目前市场上后者居多)。
3.2即时检测point-of-care test,POCT在患者近旁进行的、采用便携式分析仪器并具有操作简便和能快速得到检测结果的检测方式。
3.3精密度precision在规定的条件下,独立检测结果间的一致程度,精密度的度量通常以不精密度表示。
[来源:WS/T407—2012,3.3]3.4可比性comparability使用不同的测量程序测定某种分析物获得的检测结果间的一致性。
结果间的差异不超过规定的可接受标准时,可认为结果具有可比性。
[来源:WS/T407—2012,3.1]3.5测量区间measuring interval在规定条件下,由具有一定的仪器不确定度的测量仪器或测量系统能够测量出的一组同类量的量值,又称分析测量范围(analytic measuring range,AMR)。
[来源:WS/T420—2013,3.3]3.6标准差standard deviation,SD一个数据集中各数据与平均数离差平方的平均数的平方根,反映数据集的离散程度。
3.7变异系数coefficient of variation,CV标准差与平均数的比值,反映数据集的离散程度。
血糖监测是糖尿病管理的重要组成部分,它贯穿了糖尿病治疗与疗效评估的全过程,对糖尿病的急慢性并发症的防治具有重要作用。
2011年,中华医学会糖尿病学分会血糖监测学组发布了符合中国国情的《中国血糖监测临床应用指南(2011年版)》(以下简称《指南》)[1],目的是规范糖尿病诊疗行为、促进糖尿病的有效管理。
根据临床医护人员中针对血糖监测现况的调查,接受胰岛素治疗的患者采用自我血糖监测的比例仅20%~60%,半数医护人员认为,接受口服降糖药物治疗的患者中采取自我血糖监测的患者比例不足20%[2],且执行血糖监测的患者比例较低,每月血糖监测不足4次的患者达65.4%[3],可见我国目前的血糖监测情况不容乐观[2-8]。
为什么会造成这样的局面呢?原因在于糖尿病患者缺乏针对血糖监测的系统指导和教育,不了解血糖监测的意义和利用监测结果管理自己的病情,部分临床医师缺乏根据血糖监测结果规范治疗行为的训练,我国糖尿病患者和医护人员应加强相关知识的指导与教育[2-8]。
此外,鉴于医疗保险经费的限制,大部分糖尿病患者无法支付昂贵的血糖监测设备费用,特别是血糖试纸等,对严格按照《指南》推荐进行血糖监测造成了一定障碍[2]。
基于上述现状,《中国血糖监测临床应用指南(2015年版)》(以下简称为新版指南)[9]提出了血糖监测的基本原则,希望通过加强针对糖尿病患者和医护人员的教育,更好地控制血糖。
本文对新版指南进行了解读。
一、新版指南更新的主要内容根据临床特点将毛细血管血糖监测分为在医院内进行的床旁快速检测(POCT)和患者自主进行的SMBG,这更符合国际标准和国内临床实际需求,重视了在医院的毛细血管血糖监测管理。
基于2011年版指南在SMBG中推荐了血糖监测的频率,实际操作中各级医院的实用性反馈不一致,在新版指南中增加了血糖监测频率的指导原则,便于各级医院按照医院和患者的实际情况开展血糖监测。
在血糖监测中,如何获得准确的监测结果一直备受临床工作者的关注。
44420214364 基于ISO 15197:2003和2013标准的POCT 血糖仪比对试验结果分析胡 婷, 胡耀宗, 王伟佳, 索明环, 王 霞, 李 曼(中山大学附属中山医院检验医学中心,广东 中山 528403 )基金项目:中山市科学技术局课题(2018B1036)作者简介:胡 婷,女,1987年生,学士,主管技师,主要从事临床生物化学检测工作。
通信作者:王伟佳,联系电话:。
文章编号:1673-8640(2021)04-0444-03 中图分类号:R446.1 文献标志码:A DOI :10.3969/j.issn.1673-8640.2021.04.020近年来,即时检测(point-of-care testing ,POCT )以其便携、即时的优点,越来越广泛地被应用于临床实践。
随着我国糖尿病发病率的不断提高,相关血糖监测需求不断增加,各种品牌、方法学的POCT 血糖仪被应用于临床,但操作人员质控意识不强,也导致其检测结果的质控工作不尽如人意。
本研究参照ISO 15197:2003和2013标准,结合《便携式血糖仪临床操作和质量管理规范中国专家共识》[1]对中山大学附属中山医院POCT 血糖仪与大型生化分析仪进行比对试验,评价医院在用4个品牌的40台POCT 血糖仪的比对结果,以提高POCT 血糖仪的临床应用 价值。
1 材料和方法1.1 样本收集选取2019年6月10日中山大学附属中山医院体检者的10份肝素锂抗凝全血样本,所有样本红细胞(red blood cell ,RBC )、血红蛋白(hemoglobin ,Hb )、血细胞比容(hematocrit ,Hct )、三酰甘油(triglyceride ,TG )、尿酸(uric acid ,UA )、总胆红素(total bilirubin ,TB )检测结果均在生物学参考区间内。
选取2份样本,37 ℃温浴使葡萄糖酵解,得到葡萄糖浓度<4.2 mmol/L 的低浓度样本;另选取2份葡萄糖浓度为4.2~7.0 mmol/L 的样本作为中浓度样本;再选取2份样本,添加50~100 μL 稀释10倍的50%葡萄糖注射液,得到葡萄糖浓度为7.0~11.1 mmol/L 的高浓度样本;其他4份样本中,选2份添加约100 μL 稀释10倍的50%葡萄糖注射液,另外2份添加约200 μL 稀释10倍的50%葡萄糖注射液,得到葡萄糖浓度>11.1 mmol/L 的高浓度样本。
无创血糖/葡萄糖监测产品注册审查指导原则本指导原则旨在指导申请人对无创血糖/葡萄糖监测产品(简称“产品”)注册申报资料的准备及撰写,同时也为技术审评部门审评注册申报资料提供参考。
本指导原则是对产品的一般性要求,申请人应依据其具体特性确定其中内容是否适用,若不适用,需具体阐述理由及相应的科学依据,并依据其具体特性对注册申报资料的内容进行充实和细化。
本指导原则是供申请人和审查人员使用的指导文件,不涉及注册审批等行政事项,亦不作为法规强制执行,如有能够满足法规要求的其他方法,也可以采用,但应提供详细的研究资料和验证资料,应在遵循相关法规的前提下使用本指导原则。
本指导原则是在现行法规、标准体系及当前认知水平下制定的,随着法规、标准体系的不断完善和科学技术的不断发展,本指导原则相关内容也将适时进行调整。
参考《医疗器械安全和性能的基本原则》,申请人应明确基本的设计和生产要求,应能设计和生产在医疗器械全生命周期内均能达到预期安全和性能要求的产品。
一、范围本指导原则适用于预期采用无创方式监测人体血糖/葡萄糖的医疗器械设备或系统,对于连续无创血糖监测医疗器械产品也具有一定的参考意义。
本指导原则对产品的结构及组成、检测参数、预期用途、预期使用环境等不做限制。
产品既可以是独立设备,例如,无创血糖仪(Noninvasive Glucose Meter),又可以作为多参数模块集成在设备或系统中,例如,组合血糖仪(Hybrid Glucose Meter) 中的无创模块部分,也可以是穿戴式无创血糖/葡萄糖监测的设备或系统,例如,柔性无创血糖传感器。
本指导原则不适用于有创血糖/葡萄糖监测产品,例如,有创血糖仪、组合血糖仪的有创血糖检测模块(含试纸)、有创的持续葡萄糖监测系统(Continuous Glucose Monitoring, CGM)等。
二、技术审查要点(一) 监管信息1.申请表申请人应按照填表要求填写,其中产品名称、结构及组成、产品适用范围应与综述资料、产品说明书的相关内容保持一致。
BS EN ISO 15197:2015In vitro diagnostic test systems — Requirements for blood-glucose monitoring systemsfor self-testing in managing diabetes mellitusBS EN ISO 15197:2015BRITISH STANDARDNational forewordThis British Standard is the UK implementation ofEN ISO15197:2015.It is identical to ISO 15197:2013. Itsupersedes BS EN ISO 15197:2013which is withdrawn.The UK participation in its preparation was entrusted to TechnicalCommittee CH/212, IVDs.A list of organizations represented on this committee can beobtained on request to its secretary.This publication does not purport to include all the necessaryprovisions of a contract. Users are responsible for its correctapplication.© The British Standards Institution 2015.Published by BSI Standards Limited 2015ISBN 978 0 580 90800 2ICS 11.040.55; 11.100.10Compliance with a British Standard cannot confer immunity fromlegal obligations.This British Standard was published under the authority of theStandards Policy and Strategy Committee on 30 June 2015.Amendments/corrigenda issued since publicationDate Text affectedEUROPEAN STANDARD NORME EUROPÉENNE EUROPÄISCHE NORMEN ISO 15197 June2015ICS 11.100.10Supersedes EN ISO 15197:2013English VersionIn vitro diagnostic test systems - Requirements for blood-glucosemonitoring systems for self-testing in managing diabetes mellitus(ISO 15197:2013)Systèmes d'essais de diagnostic in vitro - Exigences relatives aux systèmes d'autosurveillance de la glycémie destinés à la prise en charge du diabète sucré (ISO15197:2013) Testsysteme für die In-vitro-Diagnostik - Anforderungen an Blutzuckermesssysteme zur Eigenanwendung bei Diabetesmellitus (ISO 15197:2013)This European Standard was approved by CEN on 3 June 2015.CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.EUROPEAN COMMITTEE FOR STANDARDIZATIONC O M I TÉ E U R OPÉE NDE N O R M A LI S A T I O NEUR O PÄIS C HES KOM I TE E FÜR NOR M UNGCEN-CENELEC Management Centre: Avenue Marnix 17, B-1000 Brussels© 2015 CEN All rights of exploitation in any form and by any means reservedworldwide for CEN national Members.Ref. No. EN ISO 15197:2015 EBS EN ISO 15197:2015EN ISO 15197:2015 (E)ForewordThe text of ISO 15197:2013 has been prepared by Technical Committee ISO/TC 212 “Clinical laboratory testing and in vitro diagnostic test systems” of the International Organization for Standardization (ISO) and has been taken over as EN ISO 15197:2015 by Technical Committee CEN/TC 140 “In vitro diagnostic medical devices” the secretariat of which is held by DIN.This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by December 2015, and conflicting national standards shall be withdrawn at the latest by June 2018.Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.This document supersedes EN ISO 15197:2013.This document has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association, and supports essential requirements of EU Directive(s).For relationship with EU Directive, see informative Annex ZA, which is an integral part of this document.The following referenced documents are indispensable for the application of this document. For undated references, the edition of the referenced document (including any amendments) listed below applies. For dated references, only the edition cited applies. However, for any use of this standard ‘within the meaning of Annex ZA’, the user should always check that any referenced document has not been superseded and that its relevant contents can still be considered the generally acknowledged state-of-art.When an IEC or ISO standard is referred to in the ISO standard text, this shall be understood as a normative reference to the corresponding EN standard, if available, and otherwise to the dated version of the ISO or IEC standard, as listed below.NOTE The way in which these referenced documents are cited in normative requirements determines the extent (in whole or in part) to which they apply.BS EN ISO 15197:2015 EN ISO 15197:2015 (E)Table — Correlation between undated normative references and dated EN and ISO standardsNormative references as listedin Clause 2Equivalent dated standardEN ISOISO 13485 EN ISO 13485:2012 + AC:2012 ISO 13485:2003 + Cor. 1:2009ISO 14971 EN ISO 14971:2012 ISO 14971:2007, Corrected version2007-10-01ISO 17511 EN ISO 17511:2003 ISO 17511:2003ISO 18113-1 EN ISO 18113-1:2011 ISO 18113-1:2009ISO 18113-4 EN ISO 18113-4:2011 ISO 18113-4:2009ISO 18113-5 EN ISO 18113-5:2011 ISO 18113-5:2009ISO 23640 EN ISO 23640:2014 ISO 23640:2011IEC 60068-2-64 EN 60068-2-64:2008 IEC 60068-2-64:2008IEC 61010-1 EN 61010-1:2010 IEC 61010-1:2010 + Cor. :2011IEC 61010-2-101 EN 61010-2-101:2002 IEC 61010-2-101:2002IEC 61326-1 EN 61326-1:2013 IEC 61326-1:2012IEC 61326-2-6 EN 61326-2-6:2013 IEC 61326-2-6:2012IEC 62366 EN 62366:2008 IEC 62366:2007EN 13612 EN 13612:2002According to the CEN-CENELEC Internal Regulations, the national standards organizations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.Endorsement noticeThe text of ISO 15197:2013 has been approved by CEN as EN ISO 15197:2015 without any modification.BS EN ISO 15197:2015EN ISO 15197:2015 (E)Annex ZA(informative)Relationship between this European Standard and the EssentialRequirements of EU Directive 98/79/ECThis European Standard has been prepared under a mandate given to CEN by the European Commission and the European Free Trade Association to provide a means of conforming to Essential Requirements of Directive 98/79/EC in vitro diagnostic medical devices.Once this standard is cited in the Official Journal of the European Union under that Directive and has been implemented as a national standard in at least one Member State, compliance with the normative clauses of this standard given in Table ZA.1 confers, within the limits of the scope of this standard, a presumption of conformity with the corresponding Essential Requirements of that Directive and associated EFTA Regulations.NOTE 1 Where a reference from a clause of this standard to the risk management process is made, the risk management process needs to be in compliance with Directive 98/79/EC. This means that risks have to be reduced ‘as far as possible’, ‘to a minimum’, ‘to the lowest possible level’, ‘minimized’ or ‘removed’, according to the wording of the corresponding essential requirement.NOTE 2 The manufacturer’s policy for determining acceptable risk must be in compliance with essential requirements Part A: 1, 2 and 5; Part B: 1.2, 2, 3, 5, 6 and 7 of the Directive.NOTE 3 This Annex ZA is based on normative references according to the table of references in the European foreword, replacing the references in the core text.NOTE 4 When an Essential Requirement does not appear in Table ZA.1, it means that it is not addressed by this European Standard.Table ZA.1 — Correspondence between this European Standard and Directive 98/79/ECClause(s)/sub-clause(s) of this EN Essential Requirements(ERs) ofDirective 98/79/ECQualifying remarks/notes4.3 A.2 Referenced clause covers only the firstbullet point of the ER.Risk management of blood glucosemonitoring instrument is not covered bythe referenced clause.Directive 98/79/EC requiresmanufacturers to eliminate or reduce risksas far as possible.For managing risks associated with invitro diagnostic medical devices ENISO 14971:2012 should be applied.5.11, 5.12 B.3.3 Referenced clauses cover only thetemperature (5.11) and humidity (5.12)aspects of the ER (in second bullet)4.4 B.3.66, 7.2 B.4.1 This ER is covered when accuracy limitsare stated by the manufacturer in the IFU.4.5 B.7.2WARNING — Other requirements and other EU Directives may be applicable to the product(s) falling within the scope of this standard.BS EN ISO 15197:2015ISO 15197:2013(E) Contents PageForeword (iv)Introduction (v)1 Scope (1)2 Normative references (1)3 Terms and definitions (2)4 Design and development (8)4.1 General requirements (8)4.2 Metrological traceability (8)4.3 Safety and risk management (9)4.4 Ergonomics and human factors (10)4.5 User verification requirements (10)5 Safety and reliability testing (10)5.1 General requirements (10)5.2 Protection against electric shock (11)5.3 Protection against mechanical hazards (11)5.4 Electromagnetic compatibility (11)5.5 Resistance to heat (11)5.6 Resistance to moisture and liquids (11)5.7 Protection against liberated gases, explosion and implosion (12)5.8 Meter components (12)5.9 Performance test (12)5.10 Mechanical resistance to vibration and shock (12)5.11 Equipment temperature exposure limits for storage (13)5.12 Equipment humidity exposure limits for storage (13)6 Analytical performance evaluation (14)6.1 General requirements (14)6.2 Measurement precision (16)6.3 System accuracy (19)6.4 Influence quantities (25)6.5 Stability of reagents and materials (30)7 Information supplied by the manufacturer (30)7.1 General requirements (30)7.2 Performance characteristics (31)7.3 Options for supplying instructions for use (31)8 User performance evaluation (31)8.1 General requirements (31)8.2 Acceptance criteria and evaluation of results (32)8.3 Selection and preparation of subjects (32)8.4 Execution of study protocol (32)8.5 Glucose reference values (33)8.6 Human factors (33)8.7 Data analysis and presentation of results (33)8.8 Evaluation of instructions for use (34)Annex A (informative) Possible interfering substances (35)Annex B (informative) Traceability chain (36)Annex C (informative) Rationale for the analytical performance requirements (38)Bibliography (45)BS EN ISO 15197:2015ISO 15197:2013(E)ForewordISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.International Standards are drafted in accordance with the rules given in the ISO/IEC Directives, Part 2. The main task of technical committees is to prepare International Standards. Draft International Standards adopted by the technical committees are circulated to the member bodies for voting. Publication as an International Standard requires approval by at least 75 % of the member bodies casting a vote.Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. ISO 15197 was prepared by Technical Committee ISO/TC 212, Clinical laboratory testing and in vitro diagnostic test systems.This second edition cancels and replaces the first edition (ISO 15197:2003), the clauses, subclauses and annexes of which have been technically revised.BS EN ISO 15197:2015ISO 15197:2013(E) IntroductionBlood-glucose monitoring systems are in vitro diagnostic medical devices used predominantly by individuals affected by diabetes mellitus. Diabetes mellitus is caused by a deficiency in insulin secretion or by insulin resistance leading to abnormally high concentrations of glucose in the blood, which may result in acute and chronic health complications. When used properly, a glucose monitoring system allows the user to monitor and take action to control the concentration of glucose present in the blood. This International Standard is intended for blood-glucose monitoring systems used by lay persons. The primary objectives are to establish requirements that result in acceptable performance and to specify procedures for demonstrating conformance to this International Standard. Minimum performance criteria for blood-glucose monitoring systems were established from the analytical requirements (precision and trueness) for individual glucose measurement results. “System accuracy” is the term used in this International Standard to communicate the analytical capability of a blood-glucose monitoring system to the intended users (i.e. lay persons), who would not be familiar with metrological terms commonly used in laboratory medicine. System accuracy describes the ability of a glucose monitoring system to produce measurement results that agree with true glucose values when the system is used as intended. The concept of “system accuracy” includes measurement bias and measurement precision.The requirements for system accuracy are based on three considerations:— the effectiveness of current technology for monitoring patients with diabetes mellitus;— recommendations of diabetes researchers as well as existing product standards and regulatory guidelines; and— the state-of-the-art of blood-glucose monitoring technology.In arriving at the performance requirements specified in the second edition of this International Standard, desirable goals had to be weighed against the capabilities of existing blood-glucose monitoring technology. The revised performance criteria in this edition are the result of improvements in technology since publication of the first edition. The considerations that formed the basis for the minimum acceptable analytical performance of a blood-glucose measuring device intended for self-monitoring are described in Annex C.Requirements that are unique to self-monitoring devices for blood-glucose are addressed in this International Standard. Requirements that apply in general to all in vitro diagnostic medical devices are incorporated by reference to other standards where appropriate.Although this International Standard does not apply to glucose monitoring systems that provide measured values on an ordinal scale (e.g. visual, semiquantitative measurement procedures) or medical devices that measure blood-glucose continuously for self-monitoring, it may be useful as a guide for developing procedures to evaluate the performance of such systems.BS EN ISO 15197:2015BS EN ISO 15197:2015 In vitro diagnostic test systems — Requirements for blood-glucose monitoring systems for self-testing in managing diabetes mellitus1 ScopeThis International Standard specifies requirements for in vitro glucose monitoring systems that measure glucose concentrations in capillary blood samples, for specific design verification procedures and for the validation of performance by the intended users. These systems are intended for self-measurement by lay persons for management of diabetes mellitus.This International Standard is applicable to manufacturers of such systems and those other organizations (e.g. regulatory authorities and conformity assessment bodies) having the responsibility for assessing the performance of these systems.This International Standard does not:— provide a comprehensive evaluation of all possible factors that could affect the performance of these systems,— pertain to glucose concentration measurement for the purpose of diagnosing diabetes mellitus,— address the medical aspects of diabetes mellitus management,— apply to measurement procedures with measured values on an ordinal scale (e.g. visual, semiquantitative measurement procedures), or to continuous glucose monitoring systems,— apply to glucose meters intended for use in medical applications other than self-testing for the management of diabetes mellitus2 Normative references The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.ISO 13485, Medical devices — Quality management systems — Requirements for regulatory purposes ISO 14971, Medical devices — Application of risk management to medical devices ISO 17511, In vitro diagnostic medical devices — Measurement of quantities in biological samples — Metrological traceability of values assigned to calibrators and control materialsISO 18113-1, In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 1: Terms, definitions and general requirementsISO 18113-4, In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 4: In vitro diagnostic reagents for self-testingISO 18113-5, In vitro diagnostic medical devices — Information supplied by the manufacturer (labelling) — Part 5: In vitro diagnostic instruments for self-testingISO 23640, In vitro diagnostic medical devices — Evaluation of stability of in vitro diagnostic reagents IEC 60068-2-64, Environmental testing — Part 2-64: Tests — Test Fh: Vibration, broadband random and guidanceINTERNATIONAL STANDARD ISO 15197:2013(E)© ISO 2013 – All rights reserved 1British Standards InstitutionProvided by IHS under license with BSI - Uncontrolled CopyLicensee=Chongqing Institute of quality and Standardization 5990390Not for Resale, 2015/8/27 08:52:05 No reproduction or networking permitted without license from IHSBS EN ISO 15197:2015 ISO 15197:2013(E)IEC 61010-1, Safety requirements for electrical equipment for measurement, control, and laboratory use — Part 1: General requirementsIEC 61010-2-101, Safety requirements for electrical equipment for measurement, control and laboratory use — Part 2-101: Particular requirements for in vitro diagnostic (IVD) medical equipmentIEC 61326-1, Electrical equipment for measurement, control and laboratory use — EMC requirements — Part 1: General requirementsIEC 61326-2-6, Electrical equipment for measurement, control and laboratory use — EMC requirements — Part 2-6: Particular requirements — In vitro diagnostic (IVD) medical equipmentIEC 62366, Medical devices — Application of usability engineering to medical devices EN 13612, Performance evaluation of in vitro diagnostic medical devices 3 Terms and definitionsFor the purposes of this document, the terms and definitions given in ISO 18113-1 and the following apply.3.1blood-glucose monitoring system measuring system consisting of a portable instrument and reagents used for the in vitro monitoring of glucose concentrations in blood Note 1 to entry: Blood-glucose monitoring systems measure glucose in capillary blood samples, but can express measured values as either the glucose concentration in capillary blood or the equivalent glucose concentration in capillary plasma. Concentrations in this International Standard refer to the type of measured values reported by the system.3.2blood-glucose meter component of a blood-glucose monitoring system that converts the product of a chemical reaction into the glucose concentration of the sample 3.3capillary blood-sample blood sample collected by skin puncture Note 1 to entry: A finger punctured by a lancet is commonly called a “fingerstick”.3.4commutability of a reference material property of a reference material, demonstrated by the closeness of agreement between the relation among the measurement results for a stated quantity in this material, obtained according to two given measurement procedures, and the relation obtained among the measurement results for other specified materials Note 1 to entry: The reference material in question is usually a calibrator and the other specified materials are usually routine samples.Note 2 to entry: The measurement procedures referred to in the definition are the one preceding and the one following the reference material (calibrator) in question in a calibration hierarchy. See ISO 17511 for further information.Note 3 to entry: The stability of commutable reference materials is monitored regularly.[ISO/IEC Guide 99:2007, definition 5.15]Note 4 to entry: Although blood would be the ideal matrix for reference materials for blood-glucose monitoring devices, such materials are not available at this time.2 © ISO 2013 – All rights reservedBritish Standards InstitutionProvided by IHS under license with BSI - Uncontrolled CopyLicensee=Chongqing Institute of quality and Standardization 5990390Not for Resale, 2015/8/27 08:52:05 No reproduction or networking permitted without license from IHSBS EN ISO 15197:2015 ISO 15197:2013(E)3.5consecutive selection method sampling method for a research study in which all subjects that meet the enrolment criteria are accepted in the order they volunteer for the study Note 1 to entry: This method will provide unbiased samples as long as no confounding variables are introduced during the trial period. For example, if a study lasts one morning, study subjects might not be representative of the target population, since subjects who visit the clinic in the morning might not be representative of all subjects who visit the clinic.Note 2 to entry: Adapted from Reference.[5]3.6disinfection process of destroying pathogenic organisms or rendering them inert Note 1 to entry: Adapted from Reference.[6]3.7influence quantity quantity that, in a direct measurement, does not affect the quantity that is actually measured, but affects the relation between the measurement indication and the measurement result EXAMPLE 1 Frequency in the direct measurement with an ammeter of the constant amplitude of an alternating current.EXAMPLE 2 Amount-of-substance concentration of bilirubin in a direct measurement of haemoglobin amount-of-substance concentration in human blood plasma.EXAMPLE 3 Temperature of a micrometer used for measuring the length of a rod, but not the temperature of the rod itself which can enter into the definition of the measurand.EXAMPLE 4 Background pressure in the ion source of a mass spectrometer during a measurement of amount-of-substance fraction.Note 1 to entry: An indirect measurement involves a combination of direct measurements, each of which may be affected by influence quantities.Note 2 to entry: Adapted from ISO/IEC Guide 99:2007, definition 2.52.3.8intermediate measurement precision intermediate precision measurement precision under a set of conditions of measurement that includes the same measurement procedure, same location and replicate measurements on the same or similar objects over an extended period of time, and can include other conditions involving changes Note 1 to entry: Interpretation of intermediate measurement precision requires that the changed and unchanged conditions be specified, particularly variables such as calibrations, reagent lots, measuring systems, operators and environmental conditions.Note 2 to entry: In evaluating IVD medical devices, the intermediate precision conditions are generally selected to represent the actual use conditions of the IVD medical device over an extended period of time.Note 3 to entry: Relevant statistical concepts are given in ISO 5725-3.Note 4 to entry: Intermediate precision can be expressed quantitatively in terms of the dispersion characteristics of the measured values, such as standard deviation, variance, and coefficient of variation.Note 5 to entry: Adapted from ISO/IEC Guide 99:2007, definitions 2.22 and 2.23.© ISO 2013 – All rights reserved 3British Standards InstitutionProvided by IHS under license with BSI - Uncontrolled CopyLicensee=Chongqing Institute of quality and Standardization 5990390Not for Resale, 2015/8/27 08:52:05 No reproduction or networking permitted without license from IHSBS EN ISO 15197:2015 ISO 15197:2013(E)3.9lay person individual without formal training in a relevant field or disciplineNote 1 to entry: For the purposes of this International Standard, a lay person is a user of a blood-glucose monitoring device who does not have specific medical, scientific or technical knowledge related to blood-glucose monitoring.Note 2 to entry: Adapted from ISO 18113-1, definition 3.34.3.10manufacturer’s selected measurement procedure measurement procedure that is calibrated by one or more primary or secondary calibrators and validated for its intended use Note 1 to entry: ISO 17511:2003, Figure 1 shows the manufacturer’s selected measurement procedure in thetraceability chain.Note 2 to entry: See ISO 17511:2003, 4.2.2 f).3.11manufacturer’s standing measurement procedure measurement procedure that is calibrated by one or more of the manufacturer’s working calibrators or higher types of calibrator and validated for its intended use Note 1 to entry: ISO 17511:2003, Figure 1 shows the manufacturer’s standing measurement procedure in the traceability chain.Note 2 to entry: See ISO 17511:2003, 4.2.2 h).3.12measurement accuracy accuracy closeness of agreement between a measured quantity value and a true quantity value of the measurand Note 1 to entry: The concept “measurement accuracy” is not a quantity and is not given a numerical quantity value. A measurement is said to be more accurate when it offers a smaller measurement error.Note 2 to entry: The term “measurement accuracy” is not used for measurement trueness and the term “measurement precision” is not used for measurement accuracy, which, however, is related to both these concepts.Note 3 to entry: “Measurement accuracy” is sometimes understood as closeness of agreement between measured quantity values that are being attributed to a measurand.[ISO/IEC Guide 99:2007, definition 2.13]3.13measurement bias bias estimate of a systematic measurement error Note 1 to entry: Bias is inversely related to trueness.Note 2 to entry: An estimation of bias is the average value of a series of measurements minus a reference quantity value.Note 3 to entry: Adapted from ISO/IEC Guide 99:2007, definition 2.18.4 © ISO 2013 – All rights reserved British Standards Institution Provided by IHS under license with BSI - Uncontrolled Copy Licensee=Chongqing Institute of quality and Standardization 5990390Not for Resale, 2015/8/27 08:52:05 No reproduction or networking permitted without license from IHS。